Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

NCT07261683 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Immunotherapy
Pembrolizumab

Interventions

DRUG: Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron

Sponsor

Obstetrics & Gynecology Hospital of Fudan University